{"preliminary_commentary":{"by_channel":{"x_thread":85,"youtube":78,"podcast":53,"x_video":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04821622\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TALAPRO-3","nct_id":"NCT04821622","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=talapro-3-nct04821622. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Talazoparib plus enzalutamide","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Placebo plus enzalutamide","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":["Astellas Pharma Inc"],"completion_date":{"date":"2027-08-28","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":599,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"talazoparib plus enzalutamide","otherNames":["Combination arm"],"type":"DRUG"},{"name":"Placebo plus enzalutamide","otherNames":["Monotherapy arm"],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Pfizer","official_title":"TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"radiological Progression-Free Survival","timeFrame":"randomization up to 3 years"}],"references":[{"citation":"Agarwal N, Matsubara N, Azad AA, Saad F, Mateo J, Jiang S, Ye D, Voog E, Shore ND, Cil T, Vulsteke C, Chung HJ, Zschabitz S, Laird AD, Zhang X, Nandoskar P, Chetcuti SF, Wang F, Fizazi K. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. N Engl J Med. 2026 Jul 30;395(5):427-439. doi: 10.1056/NEJMoa2604126. Epub 2026 May 30.","pmid":"42223064","type":"DERIVED"},{"citation":"Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2024 Mar;20(9):493-505. doi: 10.2217/fon-2023-0526. Epub 2023 Oct 26.","pmid":"37882449","type":"DERIVED"}],"start_date":{"date":"2021-05-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","url":"https://clinicaltrials.gov/study/NCT04821622"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/talapro-3-nct04821622"}